Pettyjohn Wood & White Inc. cut its holdings in shares of CVS Health (NYSE:CVS) by 7.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 66,150 shares of the pharmacy operator’s stock after selling 5,005 shares during the quarter. CVS Health comprises approximately 1.7% of Pettyjohn Wood & White Inc.’s investment portfolio, making the stock its 15th biggest position. Pettyjohn Wood & White Inc.’s holdings in CVS Health were worth $4,796,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in CVS. Ontario Teachers Pension Plan Board boosted its holdings in CVS Health by 1.4% during the 2nd quarter. Ontario Teachers Pension Plan Board now owns 937,658 shares of the pharmacy operator’s stock valued at $75,444,000 after acquiring an additional 13,224 shares during the period. Sun Life Financial INC boosted its holdings in CVS Health by 17,000.0% during the 2nd quarter. Sun Life Financial INC now owns 7,353 shares of the pharmacy operator’s stock valued at $592,000 after acquiring an additional 7,310 shares during the period. Meridian Investment Counsel Inc. boosted its holdings in CVS Health by 12.5% during the 2nd quarter. Meridian Investment Counsel Inc. now owns 12,155 shares of the pharmacy operator’s stock valued at $978,000 after acquiring an additional 1,350 shares during the period. QCM Cayman Ltd. raised its position in CVS Health by 147.6% in the 2nd quarter. QCM Cayman Ltd. now owns 11,172 shares of the pharmacy operator’s stock valued at $899,000 after purchasing an additional 6,659 shares in the last quarter. Finally, Optimum Investment Advisors raised its position in CVS Health by 20.0% in the 2nd quarter. Optimum Investment Advisors now owns 3,444 shares of the pharmacy operator’s stock valued at $277,000 after purchasing an additional 573 shares in the last quarter. Institutional investors and hedge funds own 83.97% of the company’s stock.
A number of equities research analysts have issued reports on the company. Leerink Swann set a $85.00 price target on CVS Health and gave the company a “buy” rating in a research report on Tuesday, April 10th. ValuEngine lowered CVS Health from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st. Vetr lowered CVS Health from a “buy” rating to a “hold” rating and set a $77.11 price target on the stock. in a research report on Thursday, January 4th. Morgan Stanley raised CVS Health from an “equal weight” rating to an “overweight” rating and set a $88.00 price target on the stock in a research report on Friday, January 5th. Finally, SunTrust Banks increased their price target on CVS Health to $90.00 and gave the company a “buy” rating in a research report on Friday, January 5th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $86.65.
In other news, EVP Helena Foulkes sold 19,965 shares of the firm’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $71.04, for a total transaction of $1,418,313.60. Following the sale, the executive vice president now owns 65,072 shares of the company’s stock, valued at approximately $4,622,714.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.61% of the stock is currently owned by company insiders.
Shares of NYSE CVS opened at $65.86 on Friday. The company has a current ratio of 1.02, a quick ratio of 0.52 and a debt-to-equity ratio of 0.59. CVS Health has a fifty-two week low of $60.14 and a fifty-two week high of $84.00. The stock has a market cap of $68,085.24, a PE ratio of 11.16, a price-to-earnings-growth ratio of 1.11 and a beta of 1.05.
CVS Health (NYSE:CVS) last issued its earnings results on Thursday, February 8th. The pharmacy operator reported $1.92 earnings per share for the quarter, topping the consensus estimate of $1.88 by $0.04. CVS Health had a return on equity of 17.21% and a net margin of 3.58%. The business had revenue of $48.39 billion for the quarter, compared to analyst estimates of $47.54 billion. During the same quarter last year, the company earned $1.71 EPS. The business’s quarterly revenue was up 5.3% on a year-over-year basis. equities analysts forecast that CVS Health will post 6.3 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 3rd. Stockholders of record on Monday, April 23rd will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 3.04%. The ex-dividend date of this dividend is Friday, April 20th. CVS Health’s dividend payout ratio (DPR) is presently 33.90%.
COPYRIGHT VIOLATION WARNING: “CVS Health (CVS) Shares Sold by Pettyjohn Wood & White Inc.” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another site, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/04/20/cvs-health-cvs-shares-sold-by-pettyjohn-wood-white-inc.html.
CVS Health Company Profile
CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.